Apoptosis-based therapies and drug targets
Open Access
- 21 January 2005
- journal article
- review article
- Published by Springer Nature in Cell Death & Differentiation
- Vol. 12 (S1) , 942-961
- https://doi.org/10.1038/sj.cdd.4401556
Abstract
The pathogenesis of many diseases is most closely connected with aberrantly regulated apoptotic cell death. The past 15 years have witnessed an explosion in the basic knowledge of mechanisms that regulate apoptosis and the mediators that either trigger or inhibit cell death. Consequently, great interest has emerged in devising therapeutic strategies for modulating the key molecules of life-and-death decisions. Numerous novel approaches are currently being followed employing gene therapy and antisense strategies, recombinant biologics or classical organic and combinatorial chemistry in order to target specific apoptotic regulators. Although drug development is still in its infancy, several therapeutics have progressed to clinical testing or have even been approved in record time. This review outlines the recent advances in the field of apoptosis-based therapies and explores some highlights of a very active field of drug development.Keywords
This publication has 142 references indexed in Scilit:
- The Bcl-2 family: roles in cell survival and oncogenesisOncogene, 2003
- Inhibition of papain-like cysteine proteases and legumain by caspase-specific inhibitors: when reaction mechanism is more important than specificityCell Death & Differentiation, 2003
- IAP proteins: blocking the road to death's doorNature Reviews Molecular Cell Biology, 2002
- Ablation of microvessels in vivo upon dimerization of iCaspase-9Gene Therapy, 2002
- Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compoundNature Medicine, 2002
- Discovery of Small-Molecule Inhibitors of Bcl-2 through Structure-Based Computer ScreeningJournal of Medicinal Chemistry, 2001
- The BH3 domain of BAD fused to the Antennapedia peptide induces apoptosis via its alpha helical structure and independent of Bcl-2Cell Death & Differentiation, 2001
- A small synthetic peptide, which inhibits the p53-hdm2 interaction, stimulates the p53 pathway in tumour cell lines 1 1Edited by A. R. FershtJournal of Molecular Biology, 2000
- Locoregional Apo2L/TRAIL Eradicates Intracranial Human Malignant Glioma Xenografts in Athymic Mice in the Absence of NeurotoxicityBiochemical and Biophysical Research Communications, 1999
- Predominant pathogenic role of tumor necrosis factor in experimental colitis in miceEuropean Journal of Immunology, 1997